Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Rifampicin

Generic name
Rifampicin
Brand name
ATC Code
J04AB02

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Tuberculosis
  • Oral
    • 0 years up to 1 year
      [2]
      • 10 mg/kg/day in 1 dose
    • 1 year up to 18 years and < 50 kg
      [2]
      • 10 - 20 mg/kg/day in 1 dose. Max: 450 mg/day.
    • 1 year up to 18 years and ≥ 50 kg
      [2]
      • 10 - 20 mg/kg/day in 1 dose. Max: 600 mg/dose.
  • Intravenous
    • 0 years up to 1 year
      [2]
      • 10 mg/kg/day in 1 dose
    • 1 year up to 18 years and < 50 kg
      [2]
      • 10 - 20 mg/kg/day in 1 dose. Max: 450 mg/day.
    • 1 year up to 18 years and ≥ 50 kg
      [2]
      • 10 - 20 mg/kg/day in 1 dose. Max: 600 mg/day.
Infections in cystic fibrosis
  • Oral
    • 1 month up to 18 years
      [1]
      • 20 mg/kg/day in 2 doses. Max: 1.2 g/day.
Non-tuberculosis
  • Oral
    • 1 month up to 18 years
      [1]
      • 20 mg/kg/day in 2 doses. Max: 1.2 g/day.
  • Intravenous
    • < 1 week
      [1]
      • 10 mg/kg/day in 1 dose
    • 1 week up to 1 month
      [1]
      • only if there is no hyperbilirubinaemia: 20 mg/kg/day in 2 doses. Max: 1.2 g/day.

      • In hyperbilirubinaemia: 10 mg/kg/day

    • 1 month up to 18 years
      [1]
      • 20 mg/kg/day in 2 doses. Max: 1.2 g/day.
Prophylaxis for meningococcosis
  • Oral
    • 0 months up to 3 months
      [4]
      • 10 mg/kg/day in 2 doses.
      • Duration of treatment:

        2 days

    • 3 months up to 12 years
      [4]
      • 20 mg/kg/day in 2 doses. Max: 1.2 g/day.
      • Duration of treatment:

        2 days

    • 12 years up to 18 years
      • 1.200 mg/day in 2 doses.
      • Duration of treatment:

        2 days
Prophylaxis of Haemophilus influenzae Type B (HiB) meningitis
  • Oral
    • 1 month up to 18 years
      [10]
      • 20 mg/kg/day in 1 dose. Max: 600 mg/dose. For 4 days..
    • Term neonate
      [9]
      • 10 mg/kg/day in 1 dose
      • Duration of treatment:

        4 days

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur
GFR 30-50 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur
GFR 10-30 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur
GFR < 10 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Not as a monotherapy because of the development of resistance.
Monitor the hepatic function in long-term use. Adjust dose in children with reduced hepatic function.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Hydrazides
J04AC01
Other drugs for treatment of tuberculosis
J04AK05
J04AK06
J04AK02
J04AK01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
  2. Genzyme Europe B.V, SmPC Rifadin (RVG 05766, 08755) 17-07-2021, www.geneesmiddeleninformatiebank.nl
  3. Furth van AM et al, Werkboek Infectieziekten bij Kinderen, VU Uitgeverij, 1999
  4. LCI, Richtlijn Meningokokkose - meningokokkenziekte, www.rivm.nl, 02-04-2013, http://www.rivm.nl/dsresource?objectid=rivmp:9288&type=org&disposition=inline
  5. Uptodate: UpToDate®, Pediatric Drug information: Rifampicin Topic 12767 Version 243.0, 02/19
  6. RIEMSER Pharma GmbH, SmPC, EREMFAT® i.v. 300 mg/600mg Pulver zur Herstellung einer Infusionslösung (3260.00.02/3260.01.02), 01/18
  7. RIEMSER Pharma GmbH, SmPC, EREMFAT® 150/300/450/600 mg Filmtabletten (3260.00.00/3260.01.00/3260.00.01/3260.01.01), 01/18
  8. RIEMSER Pharma GmbH, SmPC, EREMFAT® 100 mg/5 ml Granulat zur Herstellung einer Suspension zum Einnehmen (6061616.00.00), 01/18
  9. RijksInstituut voor Volksgezondheid en Milieu (RIVM), Haemophilus influenzae type b-infectie, https://lci.rivm.nl/richtlijnen/haemophilus-influenzae-type-b-infectie#profylaxe-behandeling , 4 juni 2019
  10. RIEMSER Pharma GmbH, SmPC, EREMFAT® i.v. 300 mg/600mg Pulver zur Herstellung einer Infusionslösung (3260.00.02/3260.01.02), 06/20

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes